JP2023518295A5 - - Google Patents
Info
- Publication number
- JP2023518295A5 JP2023518295A5 JP2022556568A JP2022556568A JP2023518295A5 JP 2023518295 A5 JP2023518295 A5 JP 2023518295A5 JP 2022556568 A JP2022556568 A JP 2022556568A JP 2022556568 A JP2022556568 A JP 2022556568A JP 2023518295 A5 JP2023518295 A5 JP 2023518295A5
- Authority
- JP
- Japan
- Prior art keywords
- expression sequence
- sequence encodes
- cancer
- virus
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992518P | 2020-03-20 | 2020-03-20 | |
| US62/992,518 | 2020-03-20 | ||
| PCT/US2021/023540 WO2021189059A2 (en) | 2020-03-20 | 2021-03-22 | Circular rna compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518295A JP2023518295A (ja) | 2023-04-28 |
| JP2023518295A5 true JP2023518295A5 (https=) | 2024-02-15 |
| JP7851254B2 JP7851254B2 (ja) | 2026-04-24 |
Family
ID=75539941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556568A Active JP7851254B2 (ja) | 2020-03-20 | 2021-03-22 | 環状ｒｎａ組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240245805A1 (https=) |
| EP (1) | EP4121453A2 (https=) |
| JP (1) | JP7851254B2 (https=) |
| KR (1) | KR20230069042A (https=) |
| CN (1) | CN116034114A (https=) |
| AU (1) | AU2021237738A1 (https=) |
| BR (1) | BR112022018854A2 (https=) |
| CA (1) | CA3172423A1 (https=) |
| MX (1) | MX2022011677A (https=) |
| WO (1) | WO2021189059A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112399860B (zh) | 2018-06-06 | 2024-08-16 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| AU2022234607B2 (en) | 2021-03-10 | 2025-01-23 | Rznomics Inc. | Self-circularized RNA structure |
| CN115702940A (zh) * | 2021-08-05 | 2023-02-17 | 苏州科锐迈德生物医药科技有限公司 | 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用 |
| CN113999852B (zh) * | 2021-11-30 | 2024-04-02 | 杭州市富阳区第一人民医院 | circ_0001772作为结直肠癌诊断和治疗标志物的应用 |
| EP4444361A4 (en) * | 2021-12-09 | 2025-12-10 | Carisma Therapeutics Inc | IN VIVO ADMINISTRATION TO IMMUNE CELLS |
| CN114574483B (zh) | 2022-03-02 | 2024-05-10 | 苏州科锐迈德生物医药科技有限公司 | 基于翻译起始元件点突变的重组核酸分子及其在制备环状rna中的应用 |
| CN117965543A (zh) * | 2022-03-02 | 2024-05-03 | 苏州科锐迈德生物医药科技有限公司 | 一种重组核酸分子及其在制备环状rna中的应用 |
| WO2023182948A1 (en) * | 2022-03-21 | 2023-09-28 | Bio Adventure Co., Ltd. | Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression |
| CN119768517A (zh) * | 2022-07-08 | 2025-04-04 | 上海环码生物医药有限公司 | 用于纯化环状核酸的方法和系统 |
| CA3263810A1 (en) * | 2022-08-02 | 2024-02-08 | Baylor College Of Medicine | COMPOSITIONS AND PROCESSES TO FACILITATE HEART AND LUNG REPAIR |
| EP4608871A1 (en) * | 2022-10-26 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | Cd33 antibody compositions for treating alzheimer's disease |
| WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2024112717A1 (en) * | 2022-11-21 | 2024-05-30 | Avstera Therapeutics Corp. | Mrna composition for preventing and treating cancer |
| AU2023398825A1 (en) | 2022-12-15 | 2025-06-26 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| US20250382341A1 (en) * | 2022-12-30 | 2025-12-18 | The Regents Of The University Of California | Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| AU2024211148A1 (en) * | 2023-01-27 | 2025-08-28 | The Methodist Hospital | Methods of making and isolating circular rnas and circular rna compositions |
| WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| CN116411023B (zh) * | 2023-02-24 | 2025-08-12 | 北京大学人民医院 | 一种新型环状rna成环序列构建car-t细胞及在治疗小细胞肺癌中的应用 |
| CN121358494A (zh) * | 2023-03-15 | 2026-01-16 | 旗舰创业创新第六有限责任公司 | 免疫原性组合物及其用途 |
| WO2024193634A1 (en) * | 2023-03-21 | 2024-09-26 | Ribox Therapeutics Hk Limited | Circular rna and preparation method thereof |
| WO2024220625A1 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids |
| EP4705481A2 (en) | 2023-05-05 | 2026-03-11 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| CN116284006B (zh) * | 2023-05-10 | 2023-08-25 | 北京因诺惟康医药科技有限公司 | 可电离脂质化合物、包含其的脂质载体及应用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN119015401B (zh) * | 2023-06-21 | 2025-07-08 | 浙江大学 | 一种基于rna的肿瘤疫苗、制备方法、免疫佐剂及应用 |
| WO2025007148A1 (en) | 2023-06-30 | 2025-01-02 | Orna Therapeutics, Inc. | Polymer lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2025011502A1 (zh) * | 2023-07-07 | 2025-01-16 | 仁景(苏州)生物科技有限公司 | 制备环状rna方法及用于所述方法的核酸序列 |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2025105906A1 (en) * | 2023-11-17 | 2025-05-22 | Green Cross Corporation | Novel rna construct and a method of preparing circular rna using the same |
| WO2025117969A1 (en) | 2023-12-01 | 2025-06-05 | Orna Therapeutics, Inc. | Process for manufacturing lipid nanoparticles |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| CN117919450A (zh) * | 2023-12-31 | 2024-04-26 | 上海市东方医院（同济大学附属东方医院） | 一种以吞噬细胞为载体的环状rna药物及其制备和应用 |
| CN117866948B (zh) * | 2024-01-10 | 2024-12-13 | 上海环码生物医药有限公司 | 用于纯化环状核酸的阴选方法和系统 |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| US20250353881A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| CN118222638B (zh) * | 2024-05-22 | 2024-08-13 | 中国农业大学 | 一种干扰蚯蚓目的基因表达的方法 |
| WO2025250751A1 (en) | 2024-05-31 | 2025-12-04 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026006593A1 (en) | 2024-06-28 | 2026-01-02 | Orna Therapeutics, Inc. | Synthetic internal ribosome entry sites |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US5948902A (en) | 1997-11-20 | 1999-09-07 | South Alabama Medical Science Foundation | Antisense oligonucleotides to human serine/threonine protein phosphatase genes |
| WO2001060414A2 (en) | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Genetic modification of the lung as a portal for gene delivery |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| HUE042382T2 (hu) * | 2013-09-03 | 2019-06-28 | Medimmune Ltd | Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US20190135894A1 (en) * | 2015-06-25 | 2019-05-09 | iCell Gene Therapeuticics LLC | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| EP4628587A3 (en) * | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| AU2018251187B2 (en) * | 2017-04-14 | 2024-03-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for transient gene therapy with enhanced stability |
| CN111819185A (zh) * | 2017-12-15 | 2020-10-23 | 旗舰创业创新第六有限责任公司 | 包含环状多核糖核苷酸的组合物及其用途 |
| US20190314291A1 (en) * | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| MX2020007944A (es) | 2018-02-01 | 2020-11-24 | Tufts College | Nanocomplejos similares a los lípidos y sus usos. |
| WO2019191780A1 (en) | 2018-03-30 | 2019-10-03 | Arcturus Therapeutics, Inc. | Lipid particles for nucleic acid delivery |
| CN112055695A (zh) * | 2018-05-01 | 2020-12-08 | 弗莱德哈钦森癌症研究中心 | 用于基因表达的纳米粒子和其用途 |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| AU2019310448A1 (en) * | 2018-07-24 | 2021-03-11 | Mayo Foundation For Medical Education And Research | Circularized engineered rna and methods |
| BR112021023411A2 (pt) * | 2019-05-22 | 2022-02-01 | Massachusetts Inst Technology | Composições e métodos de rna circular |
-
2021
- 2021-03-22 JP JP2022556568A patent/JP7851254B2/ja active Active
- 2021-03-22 KR KR1020227036619A patent/KR20230069042A/ko active Pending
- 2021-03-22 US US17/996,074 patent/US20240245805A1/en active Pending
- 2021-03-22 CN CN202180036474.XA patent/CN116034114A/zh active Pending
- 2021-03-22 BR BR112022018854A patent/BR112022018854A2/pt unknown
- 2021-03-22 CA CA3172423A patent/CA3172423A1/en active Pending
- 2021-03-22 EP EP21719357.2A patent/EP4121453A2/en active Pending
- 2021-03-22 MX MX2022011677A patent/MX2022011677A/es unknown
- 2021-03-22 WO PCT/US2021/023540 patent/WO2021189059A2/en not_active Ceased
- 2021-03-22 AU AU2021237738A patent/AU2021237738A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518295A5 (https=) | ||
| US20240173382A1 (en) | Therapeutic RNA | |
| Takeuchi et al. | Phase II/III results of a trial of anti–tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis | |
| Park et al. | Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer | |
| JP2022533796A5 (https=) | ||
| Holzgruber et al. | Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade | |
| Avci et al. | Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? B. Avci et al. | |
| Tanaka et al. | Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial) | |
| JP2023504568A5 (https=) | ||
| WO2019232477A2 (en) | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies | |
| RU2015148920A (ru) | Расширенная адоптивная клеточная терапия | |
| Tanaka et al. | Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a phase II/III study (OHZORA trial) | |
| JP2020520922A (ja) | Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製 | |
| RU2018130752A (ru) | Введение сконструированных т-клеток для лечения рака центральной нервной системы | |
| Lajoie-Kadoch et al. | TNF-α and IFN-γ inversely modulate expression of the IL-17E receptor in airway smooth muscle cells | |
| Datta et al. | Cytokine Storm and its Implication in Coronavirus disease 2019 (COVID-19) | |
| CN119307525A (zh) | 基于i型内含子的rna体外环化与滚环翻译的方法及其应用 | |
| AU2020354654A1 (en) | NK engager compounds that bind viral antigens and methods of use | |
| WO2022098756A1 (en) | Chimeric antigen receptor cell therapy | |
| JPH10506538A (ja) | Ｇｐ１３０に全く結合することができないヒトインターロイキン−６の拮抗薬、および医薬化合物の製造におけるそれらの使用 | |
| JP2024503703A5 (https=) | ||
| Gowda et al. | Repurposing methotrexate in dampening SARS-CoV2-S1-mediated IL6 expression: lessons learnt from lung cancer | |
| Kudling et al. | Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes | |
| JP2024536109A5 (https=) | ||
| An et al. | Interleukin-22 facilitates the interferon-λ-mediated production of tripartite motif protein 25 to inhibit replication of duck viral hepatitis A virus type 1 |